Barclays
CASI

Barclays’s CASI Pharmaceuticals CASI Stock Holding History

Barclays’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-976
Closed -$12K – 4169
2021
Q3 		$12K Sell
976
-247
-20% -$3.34K ﹤0.01% 4489
2021
Q2 		$19K Sell
1,223
-4,304
-78% -$72.4K ﹤0.01% 4505
2021
Q1 		$133K Buy
5,527
+3,393
+159% +$95.3K ﹤0.01% 3886
2020
Q4 		$63K Sell
2,134
-843
-28% -$18.3K ﹤0.01% 4317
2020
Q3 		$46K Buy
2,977
+14
+0.5% +$264 ﹤0.01% 4646
2020
Q2 		$73K Buy
2,963
+1,298
+78% +$28.2K ﹤0.01% 4719
2020
Q1 		$34K Sell
1,665
-3,378
-67% -$80.6K ﹤0.01% 5426
2019
Q4 		$156K Buy
5,043
+2,557
+103% +$82.9K ﹤0.01% 5208
2019
Q3 		$83K Sell
2,486
-765
-24% -$24.6K ﹤0.01% 5611
2019
Q2 		$104K Buy
3,251
+1,841
+131% +$58.8K ﹤0.01% 5660
2019
Q1 		$40K Buy
+1,410
New +$49.1K ﹤0.01% 6024
2018
Q4 		– Sell
-2,360
Closed -$110K – 6961
2018
Q3 		$110K Buy
2,360
+1,983
+526% +$138K ﹤0.01% 5459
2018
Q2 		$31K Sell
377
-4,243
-92% -$286K ﹤0.01% 5940
2018
Q1 		$193K Sell
4,620
-2,052
-31% -$76.6K ﹤0.01% 4858
2017
Q4 		$217K Buy
+6,672
New +$181K ﹤0.01% 4613

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Barclays's CASI Position: Q4 2021 in Review

Barclays sold out of CASI Pharmaceuticals (CASI) in Q4 2021, closing a stake of 976 shares — an estimated $12K sold.

Barclays first reported a position in CASI in Q4 2017 and held it in 15 quarters. The position peaked at $217K in Q4 2017. 51 funds tracked by Wall St. Rank hold CASI as of Q4 2021.

  • Barclays reported no remaining CASI Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Barclays sold 976 CASI Pharmaceuticals shares in Q4 2021, an estimated $12K.
  • Barclays first reported a position in CASI Pharmaceuticals in Q4 2017 and held it in 15 quarters.
  • Barclays's CASI Pharmaceuticals position peaked at $217K in Q4 2017.
  • 51 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q4 2021.

Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.